Vaccinex Inc. has announced a $60 million revenue sharing agreement with Pepinemab Development Venture, LP (PDV) to fund an expanded Phase 2b clinical trial of pepinemab, an anti-SEMA4D antibody, for the treatment of Alzheimer’s disease. The agreement follows promising data from animal models and early clinical trials, including the SIGNAL-AD phase 1/2a study, which indicated that pepinemab was well-tolerated and may slow cognitive decline when administered early in the disease. Recent findings presented at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference in December 2025 demonstrated that pepinemab treatment reduced the representation of Ast10 astrocytes in the brain, a subset associated with cognitive decline, and this reduction appeared to correlate with slower cognitive decline compared to placebo. The company is continuing the development of pepinemab based on these biological, clinical, and genetic findings.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vaccinex Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9616413) on December 23, 2025, and is solely responsible for the information contained therein.